Plasma homocysteine in early and late pregnancies complicated with preeclampsia and isolated intrauterine growth restriction

Acta Obstet Gynecol Scand. 2004 Feb;83(2):155-8. doi: 10.1111/j.0001-6349.2004.00291.x.

Abstract

Background: Elevated circulating homocysteine is an independent risk factor for cardiovascular disease. Increased homocysteine plasma levels have been reported to occur in approximately 20-30% of women with preeclampsia and it has been suggested that they may predict the subsequent development of preeclampsia.

Methods: In a cohort of 1874 pregnant women followed longitudinally, who participated in the Down screening program, 27 developed preeclampsia and 36 intrauterine growth restriction (IUGR). A control group of 63 uneventful pregnancies was selected. Plasma homocysteine was assayed in the early second trimester and at delivery in all groups. Data were compared with Wilcoxon's matched-pair test.

Results: No statistically significant difference of plasma homocysteine between controls and preeclamptic or IUGR pregnancies in the early second trimester were found. There was a significant difference, only at delivery, between the preeclamptic subjects and the controls.

Conclusions: We failed to demonstrate a plasma homocysteine predictive value in pregnancies subsequently complicated by preeclampsia and IUGR. As previously stated, we found that an elevated homocysteine plasma level is associated with overt preeclampsia.

MeSH terms

  • Adult
  • Case-Control Studies
  • Cohort Studies
  • Down Syndrome / epidemiology
  • Female
  • Fetal Growth Retardation / blood*
  • Fetal Growth Retardation / complications
  • Homocysteine / blood*
  • Humans
  • Hyperhomocysteinemia / blood
  • Hyperhomocysteinemia / complications*
  • Longitudinal Studies
  • Mass Screening
  • Pre-Eclampsia / blood*
  • Pre-Eclampsia / complications
  • Predictive Value of Tests
  • Pregnancy
  • Pregnancy Trimester, Second
  • Risk Factors

Substances

  • Homocysteine